Turning Point Therapeutics, Inc. - Common stock (NQ:TPTX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 16, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Turning Point Therapeutics, Inc. - Common stock

< Previous 1 2 Next >

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 13, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Turning Point Reveals Topline Data From Pivotal Repotrectinib Trial In Lung Cancer Setting ↗

April 13, 2022

Turning Point Therapeutics Inc (NASDAQ: TPTX)

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 04, 2022

Gainers Trevi Therapeutics (NASDAQ:TRVI) ...

Via Benzinga

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

FDA Clears Turning Point's IND For Elzovantinib + Aumolertinib Combo Regime In Lung Cancer Setting ↗

January 20, 2022

The FDA has signed off Turning Point Therapeutics Inc's (NASDAQ: TPTX) Investigational New Drug (IND) application for elzovantinib + aumolertinib combo therapy...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 14, 2022

During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗

October 18, 2021

Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news....

Via Benzinga

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗

November 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...

Via Benzinga

The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗

October 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

October 12, 2021

Evercore ISI Group raised Lear Corporation (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021 ↗

October 11, 2021

Upgrades According to Vertical Research, the prior rating for C.H. Robinson Worldwide Inc (NASDAQ:

Via Benzinga

Turning Point Reveals Early Repotrectinib Data In NTRK+ Advanced Solid Tumors ↗

October 08, 2021

Turning Point Therapeutics Inc (NASDAQ: TPTX) announced early data from TRIDENT-1 Phase 1/2 study of its lead drug candidate repotrectinib. In the NTRK-positive TKI-na...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

45 Biggest Movers From Yesterday ↗

October 08, 2021

Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 07, 2021

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of their outstanding shares is at $417.9 million....

Via Benzinga

Turning Point Shares Plunge After Highlighting Updated Data From Lead Program In Pretreated Lung Cancer Patients ↗

October 07, 2021

Turning Point Therapeutics Inc (NASDAQ: TPTX) has announced additional preliminary data from ongoing trials of lead drug candidate repotrectinib and elzovantinib (...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding...

Via Talk Markets

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

Turning Point's TPX-0022 In Gastric Cancer Gets Orphan Drug Designation In US ↗

June 17, 2021

The FDA has granted Orphan Drug Designation to Turning Point Therapeutics Inc's (NASDAQ: TPTX) TPX-0022, for gastric cancer, including gastroesophageal...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗

September 30, 2021

Upgrades For Cabot Oil & Gas Corp (NYSE:COG),...

Via Benzinga

85 Biggest Movers From Yesterday ↗

August 11, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive interim results from the Phase 1 trial with FTX...

Via Benzinga

54 Stocks Moving In Tuesday's Mid-Day Session ↗

August 10, 2021

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy...

Via Benzinga

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗

May 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.